Ambiq Micro, Inc.
NYSE:AMBQSemiconductors
+$5.10 today
- Market cap
- $1.14B
- Beta
- 5.68
- P/E (TTM)
- -44.8
- EPS (TTM)
- -$1.88
Volume 0.30M
Average 0.58M
AMBQ Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ambiq Micro, Inc.NYSE: AMBQ
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $12.83M rose 47.7% year over year, ahead of the +17.1% change in trailing-twelve-month research & development. Sequentially, it rose 6.8% from the prior quarter.
Context
- Research & development amounted to 46.5% of revenue in FY2025, down 2.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +47.7% holds above the trailing-twelve-month pace of +17.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 33.69M USD
- Year-over-year change
- -9.4%
- 5-year CAGR
- +3.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.69M | -9.4% |
| FY2024 | 2024-12-31 | 37.17M | -15.6% |
| FY2023 | 2023-12-31 | 44.02M | — |
| FY2021 | 2021-12-31 | 36.11M | +29.9% |
| FY2020 | 2020-12-31 | 27.79M | — |
Research & Development vs competitors
How AMBQ compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.1% is the 3rd highest of 11, against a peer median of +6.8%.
- Research & development amounts to 52.1% of revenue for AMBQ, versus a peer median of 30.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $121.4M USD | -38.5% | +7.1% | 17.0% | |
| LTM Mar 2026 | $108.55M USD | +7.9% | -3.0% | 35.9% | |
| LTM Apr 2026 | $75.88M USD | -10.9% | -6.7% | 23.8% | |
| LTM Mar 2026 | $52.5M USD | +14.1% | +6.6% | 68.2% | |
| LTM Mar 2026 | $45.54M USD | +3.0% | +11.7% | 30.4% | |
| LTM Mar 2026 | $44.12M USD | +5.7% | +13.1% | 17.7% | |
AMBQAmbiq Micro, Inc. | LTM Mar 2026 | $42.63M USD | +17.1% | — | 52.1% |
| LTM Mar 2026 | $28.96M USD | +16.8% | — | 71.8% | |
| LTM Mar 2026 | $19.41M USD | +43.2% | +18.9% | 1375.2% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.28M CNY | -94.8% | -61.3% | — |
| LTM Sep 2026 | $13M USD | +20.5% | -13.4% | 7.6% | |
| Peer median (excluding AMBQ) | — | +6.8% | +6.6% | 30.4% | |
Competitors are the stored peer set for AMBQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2020 Dec 2020 | FY2021 Dec 2021 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.97M | 91.01M | 65.54M | 76.07M | 72.51M |
| Cost of Revenue | 29.4M | 60.24M | 46.1M | 51.78M | 46.82M |
| Gross Profit | 21.57M | 30.77M | 19.44M | 24.29M | 25.7M |
| Gross Margin | 42.3% | 33.8% | 29.7% | 31.9% | 35.4% |
| Research & Development | 27.79M | 36.11M | 44.02M | 37.17M | 33.69M |
| Selling, General & Admin | 14M | 19.13M | 26.74M | 27.74M | 33.15M |
| Operating Expenses | 41.79M | 55.87M | 70.76M | 64.9M | 66.84M |
| Depreciation & Amortization | 1.93M | 2.61M | 7.72M | 6.25M | 7.22M |
| EBITDA | (18.29M) | (21.85M) | (42.59M) | (33.39M) | (29.21M) |
| EBITDA Margin | -35.9% | -24.0% | -65.0% | -43.9% | -40.3% |
| Operating Income | (20.22M) | (25.1M) | (51.32M) | (40.61M) | (41.14M) |
| Operating Margin | -39.7% | -27.6% | -78.3% | -53.4% | -56.7% |
| Interest Income | 0 | 43K | 0 | 0 | 0 |
| Interest Expense | 4.58M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.98M) | (216K) | 1.02M | 980K | 4.72M |
| Income Before Tax | (25.2M) | (25.32M) | (50.3M) | (39.63M) | (36.42M) |
| Pre-Tax Margin | -49.4% | -27.8% | -76.8% | -52.1% | -50.2% |
| Income Tax Expense | 25K | 25K | 30K | 28K | 40K |
| Net Income | (25.22M) | (25.34M) | (50.33M) | (39.66M) | (36.46M) |
| Net Margin | -49.5% | -27.8% | -76.8% | -52.1% | -50.3% |
| EPS (Basic) | (1.85) | (0.10) | (5.00) | (3.13) | (4.57) |
| EPS (Diluted) | (1.85) | (0.10) | (5.00) | (3.13) | (4.57) |
| Weighted Avg Shares | 13.61M | 248.89M | 10.45M | 13.54M | 7.98M |
| Weighted Avg Shares (Diluted) | 13.61M | 248.89M | 10.45M | 13.61M | 7.98M |
Ambiq Micro, Inc.
NYSE:AMBQ
Intrinsic Alpha fair value
Locked
Current Price
$45.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.